Phase II Trial of PS-341 in Patients With Hepatocellular Carcinoma
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2007 Status changed from in suspended to in progress.
- 17 Aug 2005 New trial record.